Cancer is one of the world’s leading causes of death affecting one in three of all people in Western countries. A recent WHO report highlights a 70% increase in the incidence of cancer worldwide from 14 million to 25 million people diagnosed with the disease each year over the next two decades.
In addition to the high cost of cancer ($895 billion / year) the human suffering associated with the disease is great.
The ethos of Px HealthCare, is to put patients first and make a real difference to their lives and quality of life. Through OWise, our mission is to provide smart digital tools that support cancer patients from the moment of diagnosis.
Px has developed cancer specific, digital health platforms that combines Patient-Experience with Advanced Data-Analytics to improve clinical outcomes in oncology.
to improve patients’ experience of treatment and their clinical outcomes with personalised, medical mobile support tools. Helping them to be better informed and more in control.
to deliver global or national Patient Reported Outcome data providing insights into the effectiveness of treatments and patients’ experience. We conducting real world clinical research on a global or national scale through our accredited app that is already in the hands of the patient.
to provide a real time monitoring platform for clinicians, improving outcomes, treatment adherence and delivering cost savings.
OWise breast is the accredited mobile app and website that helps you regain control of your life from the first day of a breast cancer diagnosis. OWise provides safe, reliable and credible information as well as practical support and guidance.
You can monitor and share changes of your day-to-day wellbeing, side effects and symptoms with your care team or other trusted individuals. This way you can help your doctors to make timely and informed decisions on how to give you more personalised care.
OWise prostate cancer has been developed to give personalised support to those with prostate cancer. OWise is your own personal cancer support app to help you regain control of your life from the first day of diagnosis. Let OWise support you with safe and reliable information while collating valuable insights about your day-to-day wellbeing that can assist your medical team in making informed decisions about on-going treatment.
Established by medical scientists in 2012 (Amsterdam, the Netherlands) and headquartered in London (UK).
Founder Dr. Anne Bruinvels has devoted much of her international career to the development of more effective, personalized drug treatments and diagnostic tools.
She previously founded and exited a data-mining biotechnology company (Curidium, which was listed on London Stock Exchange).
Dr. David Bruinvels (Medical Director and Anne’s brother) is an occupational physician specialized in oncology in addition to being a qualified epidemiologist.
A systematic review that evaluated if breast cancer apps can support patients, whereby the OWise app received the highest score.
Lidington et al., 2020; BMC. OWise is being assessed by the randomised clinical trial ADAPT at the Royal Marsden NHS Foundation Trust. Find out more here:
Px Healthcare won £60,000 in funding from the Scottish Government to keep developing their products and scale them across Scotland.
Cruz et al., 2019; JMIR. Systematic review concluded that mobile apps for women with breast cancer might be an acceptable information source that can improve patient well-being.
Adam et al., 2019; BMJ Open. Review of 151 cancer apps for individuals living with and beyond cancer.
A case study example in the NICE evidence standard framework for digital health technologies.
OWise was one of the projects selected to win the finals and progress to phase two of the Cancer Innovation Challenge!
2017 Annual British Oncology Pharmacy Association Symposium
OWise was CE-marked to comply with the European regulatory standards for safety and usage on the 7th of May, 2014.
Anne joined the NHS Innovation Accelerator (NIA) from the Netherlands … Continue reading “NHS Innovation Accelerator”
Young-Afat et al., 2016; JMIR Cancer. Independent study analysed OWise app. Read more to know what the study found!
2016 NCRI Conference
Young-Afat et al, 2014; Amsterdam EBCC9.